BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Thaddeus Tarpey

Thaddeus Tarpey contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
MethodologyApplications

Trust snapshot

Quick read

Trust 21 - EmergingVerification L1Unclaimed author
7works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

7 published item(s)

preprint2026arXiv

Clarifying identification and estimation of treatment effects in the Sequential Parallel Comparison Design

Sequential parallel comparison design (SPCD) clinical trials aim to adjust active treatment effect estimates for placebo response to minimize the impact of placebo responders on the estimates. This is potentially accomplished using a two stage design by measuring treatment effects among all participants during the first stage, then classifying some placebo arm participants as placebo non-responders who will be re-randomized in the second stage. In this paper, we use causal inference tools to clarify under what assumptions treatment effects can be identified in SPCD trials and what effects the conventional estimators target at each stage of the SPCD trial. We further illustrate the highly influential impact of placebo response misclassification on the second stage estimate. We conclude that the conventional SPCD estimators do not target meaningful treatment effects.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

A Single Index Model for Longitudinal Outcomes to Optimize Individual Treatment Decision Rules

A pressing challenge in medical research is to identify optimal treatments for individual patients. This is particularly challenging in mental health settings where mean responses are often similar across multiple treatments. For example, the mean longitudinal trajectories for patients treated with an active drug and placebo may be very similar but different treatments may exhibit distinctly different individual trajectory shapes. Most precision medicine approaches using longitudinal data often ignore information from the longitudinal data structure. This paper investigates a powerful precision medicine approach by examining the impact of baseline covariates on longitudinal outcome trajectories to guide treatment decisions instead of traditional scalar outcome measures derived from longitudinal data, such as a change score. We introduce a method of estimating "biosignatures" defined as linear combinations of baseline characteristics (i.e., a single index) that optimally separate longitudinal trajectories among different treatment groups. The criterion used is to maximize the Kullback-Leibler Divergence between different treatment outcome distributions. The approach is illustrated via simulation studies and a depression clinical trial. The approach is also contrasted with more traditional methods and compares performance in the presence of missing data.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Bayesian index models for heterogeneous treatment effects

The general idea of this article is to develop a Bayesian model with a flexible link function connecting an exponential family treatment response to a linear combination of covariates and a treatment indicator and the interaction between the two. Generalized linear models allowing data-driven link functions are often called "single-index models," and among popular semi-parametric modeling methods. In this article, we will focus on modeling heterogeneous treatment effects, with the goal of developing a treatment benefit index (TBI) incorporating prior information from historical data. This treatment benefit index can be useful for stratifying patients according to their predicted treatment benefit levels and can be especially useful for precision health applications. The proposed method is applied to a COVID-19 treatment study.

0 citations0 reviewsNo code linkedOpen access
preprint2021arXiv

A single-index model with a surface-link for optimizing individualized dose rules

This paper focuses on the problem of modeling and estimating interaction effects between covariates and a continuous treatment variable on an outcome, using a single-index regression approach. The primary motivation is to estimate an optimal individualized dose rule in an observational study. To model possibly nonlinear interaction effects between patients' covariates and a continuous treatment variable, we employ a two-dimensional penalized spline regression on an index-treatment domain, where the index is defined as a linear projection of the covariates. The method is illustrated using two applications as well as simulation experiments. A unique contribution of this work is in the parsimonious (single-index) parametrization specifically defined for the interaction effect term.

0 citations0 reviewsNo code linkedOpen access
preprint2021arXiv

Functional additive models for optimizing individualized treatment rules

A novel functional additive model is proposed which is uniquely modified and constrained to model nonlinear interactions between a treatment indicator and a potentially large number of functional and/or scalar pretreatment covariates. The primary motivation for this approach is to optimize individualized treatment rules based on data from a randomized clinical trial. We generalize functional additive regression models by incorporating treatment-specific components into additive effect components. A structural constraint is imposed on the treatment-specific components in order to provide a class of additive models with main effects and interaction effects that are orthogonal to each other. If primary interest is in the interaction between treatment and the covariates, as is generally the case when optimizing individualized treatment rules, we can thereby circumvent the need to estimate the main effects of the covariates, obviating the need to specify their form and thus avoiding the issue of model misspecification. The methods are illustrated with data from a depression clinical trial with electroencephalogram functional data as patients' pretreatment covariates.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

A constrained sparse additive model for treatment effect-modifier selection

Sparse additive modeling is a class of effective methods for performing high-dimensional nonparametric regression. This paper develops a sparse additive model focused on estimation of treatment effect-modification with simultaneous treatment effect-modifier selection. We propose a version of the sparse additive model uniquely constrained to estimate the interaction effects between treatment and pretreatment covariates, while leaving the main effects of the pretreatment covariates unspecified. The proposed regression model can effectively identify treatment effect-modifiers that exhibit possibly nonlinear interactions with the treatment variable, that are relevant for making optimal treatment decisions. A set of simulation experiments and an application to a dataset from a randomized clinical trial are presented to demonstrate the method.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Sufficient Dimension Reduction for Interactions

Dimension reduction lies at the heart of many statistical methods. In regression, dimension reduction has been linked to the notion of sufficiency whereby the relation of the response to a set of predictors is explained by a lower dimensional subspace in the predictor space. In this paper, we consider the notion of a dimension reduction in regression on subspaces that are sufficient to explain interaction effects between predictors and another variable of interest. The motivation for this work is from precision medicine where the performance of an individualized treatment rule, given a set of pretreatment predictors, is determined by interaction effects.

0 citations0 reviewsNo code linkedOpen access